跳至主要内容
临床试验/KCT0005707
KCT0005707尚未招募未知

A 12 weeks, randomized, double-blinded, placebo-controlled study of KBH-HM01 to evaluate efficacy and safety on immune function

KolmarBNH0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
45(Year) 至 70(Year)(—)
性别
All

入选标准

  • 1. Male or female subjects aged from 45 to 70 years old.
  • 2. Subjects who signed written informed consent voluntarily.
  • 3. white blood cell (WBC) ranged from 4,000 to 6,000/µl.
  • 4. Subjects suffered from upper respiratory tract infection or cold-related symptoms which have possibilities to cause upper respiratory tract infection more than two times in the past one year. (*Tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, rhinitis, etc.)

排除标准

  • 1. History or presence of sensitivity or allergic to drugs or functional food including Angelica gigas Nakai,Cnidium officinale Makino,Paeonia lactiflora Pallas
  • 2. Immune-related diseases, such as liver diseases including active hepatitis, leukemia, inflammatory systemic diseases, metabolic syndrome, infectious diseases, autoimmune diseases, etc.
  • 3. Dementia, brain tumors, hydrocephalus, or who have conducted or are undergoing hormone replacement therapy within the last 4 weeks.
  • 4. Stroke, heart disease (cardiac failure, arrhythmia, myocardial infarction, using implantable defibrillator), malignant tumor, angle close glaucoma, uncontrolled hypertension (SBP 140mmHg or higher or DBP 90mmHg or higher), lung disease, respiratory disease.
  • 5. Serum creatinine> 2.0 mg/dl, AST (aspartate aminotransferase) or ALT (alanine aminotransferase) is more than 2.5 times the normal upper limit.
  • 6. Insulin injection, FBS (fasting blood sugar) level is greater than 160 mg/dl even taking drugs to control blood sugar.
  • 7. Any of the following below
  • a) Platelet =100*103
  • b) WBC 4,000-10,000/ul
  • 8. Taking oral steroids, hormones, etc. within the last 4 weeks or has taken drugs that affect the absorption, metabolism, and excretion of investigational product.
  • 9. Took other investigational product or participated clinical trial medicines within the last 3 months
  • 10. Surgical surgery within the last 6 months or receiving prohibited treatment within 4 weeks (medical food for enhanced immunity, herbal medicine, or medication for possible abuse).
  • 11. Surgery that may affect the absorption of drugs, such as gastrointestinal dysfunction or gastrointestinal resection.
  • 12. Thyroid disease (hypothyroid or hormonal abnormalities/hypothyroidism).
  • 13. Neurological and mental disorders (depression, schizophrenia) and psychotherapy.
  • 14. Surgery (including childbirth) or cancer patients within the last 6 months.
  • 15. Drug addicts and subjects who have taken vaccine, immunosuppressants, nonsteroidal anti-inflammatory drugs, steroids, and antihistamines within the last 3 months.
  • 16. Fertile woman who disagrees with the choice of pregnant women, breastfeeding women and appropriate contraceptive methods (oral contraceptives, hormone transplants, intrauterine instruments, condoms, and spermicide).
  • 17. Immunosuppressive drugs or other immuno-improvement functional foods within the last 4 weeks.
  • 18. Donated whole blood within the last 2 months or donated blood components within 4 weeks.
  • 19. Taken antibiotics for more than 7 days.
  • 20. Judged by the investigators to be inappropriate for the clinical trial

研究者

发起方
KolmarBNH

相似试验